Abstract title: Seladelpar Is Associated With a Sustained Reduction in Cholestatic Markers and a Consistent Safety Profile in Patients With Primary Biliary Cholangitis Treated up to 48 Months in the Ongoing, Open-Label ASSURE Study
 
AASLD 2025 Nov 7 Wash DC
 
Daniel Pratt1*, Eric J. Lawitz2, Christopher L. Bowlus3, Kyung Min Kwon4, Sarah Proehl4, Xin Qi4, Robert P. Kustra4, Alejandra M. Villamil5